Suspected Guillain-Barré Syndrome
Progressive symmetric weakness with areflexia
All Pathways
NeurologyEmergency
Guillain-Barré Syndrome Management
Guillain-Barré Syndrome Management: Suspected Guillain-Barré Syndrome → Confirm Clinical Features → Assess Severity → Mild GBS (Can Walk) → Cannot Walk ...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Action Confirm Clinical Features
Brighton criteria for diagnosis
- Bilateral flaccid weakness
- Decreased/absent deep tendon reflexes
- Monophasic illness pattern
- Disease nadir: 12 hours to 28 days
- CSF: albuminocytologic dissociation
03Decision Assess Severity
Can patient walk unaided?
- GBS Disability Scale
- 0 = Healthy
- 1 = Minor symptoms
- 2 = Walks without support
- 3 = Walks with support
- 4 = Bedridden/wheelchair
- 5 = Requires ventilation
- 6 = Death
04Action Mild GBS (Can Walk)
Monitor closely, treatment optional
- Close observation for progression
- Serial respiratory assessments
- Immunotherapy if progressing
- Pain management
05Action Cannot Walk Unaided
Immunotherapy indicated
- IVIG or PLEX within 2-4 weeks of onset
- ICU admission if progressing
- Serial FVC monitoring q4h
- DVT prophylaxis
06Decision Respiratory Status
Assess for impending failure
- 20/30/40 rule: FVC<20, NIF<-30, MEP<40 = ICU
- FVC <15 mL/kg = consider intubation
- FVC declining >30%/24h = escalate
- Note: 20/30/40 from Lawn 2001 (limited evidence)
07Action Mechanical Ventilation
Early intubation if criteria met
- ~25% of GBS patients require intubation
- Avoid succinylcholine (hyperkalemia risk)
- Plan for prolonged ventilation (weeks)
- Tracheostomy if >2 weeks expected
08Decision Select Immunotherapy
IVIG vs Plasma Exchange
- Equally effective (Class I evidence)
- Treat within 2 weeks (IVIG) or 4 weeks (PLEX)
- Do NOT combine sequentially
- Steroids NOT effective in GBS
09Action IVIG
0.4 g/kg/day × 5 days
- Total dose: 2 g/kg
- Monitor renal function
- Risk: headache, aseptic meningitis
- Contraindicated: IgA deficiency
10Action Supportive Care
Essential throughout hospitalization
- DVT prophylaxis (LMWH)
- Pain management (gabapentin, opioids)
- Autonomic monitoring (BP, HR)
- Physical/occupational therapy
- Nutrition support
11Warning ⚠️ Autonomic Dysfunction
Present in 70% of severe GBS
- Cardiac arrhythmias
- Blood pressure lability
- Urinary retention
- Ileus
- Requires ICU monitoring
12Action Prognosis Assessment
Modified Erasmus GBS Outcome Score (mEGOS)
- Age, diarrhea, GBS disability score
- ~80% recover to walk independently
- 5% mortality
- Recovery over months to years
13Outcome Recovery Phase
Rehabilitation and follow-up
- Inpatient rehab if needed
- Monitor for treatment-related fluctuations
- Consider CIDP if relapsing >8 weeks
14Warning Poor Response
Consider additional evaluation
- Second course NOT routinely recommended
- Re-evaluate diagnosis (CIDP?)
- Supportive care, prolonged rehab
- Some advocate repeat IVIG if worsening
15Action Plasma Exchange
4-5 exchanges over 1-2 weeks
- 200-250 mL/kg total volume
- Replacement: 5% albumin
- May be faster onset than IVIG
- Avoid in hemodynamic instability
- Path rejoins step 10Shared downstream outcome
- Path rejoins step 08Shared downstream outcome
- Path rejoins step 05Shared downstream outcome
Guideline Source
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not cover all GBS variants in detail (Miller Fisher, etc.)
- Requires ICU capabilities for severe cases
- Autonomic dysfunction management simplified
- Pediatric dosing may differ
Applicable Regions
USEUglobal
EU: EAN/PNS 2023 recommendations followed
US: IVIG and PLEX equally effective; AAN affirms 2024
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Guillain-Barré Syndrome Management?
The Guillain-Barré Syndrome Management is a emergency clinical algorithm for Neurology. It provides a structured decision tree to guide clinical decision-making, based on European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
What guideline is the Guillain-Barré Syndrome Management based on?
This algorithm is based on European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome (DOI: 10.1111/ene.16073).
What are the limitations of the Guillain-Barré Syndrome Management?
Known limitations include: Does not cover all GBS variants in detail (Miller Fisher, etc.); Requires ICU capabilities for severe cases; Autonomic dysfunction management simplified; Pediatric dosing may differ. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Guillain-Barré Syndrome Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free